Skip to Main Content

Off-the-shelf treatments for cancer made from genetically engineered T cells and natural killer, or NK, cells have each shown promise in clinical trials. On Thursday, two biotech companies — Nkarta and CRISPR Therapeutics — announced a partnership that aims to merge the two immune-cell approaches together.

The ultimate goal of the equal partnership formed by the two companies is to develop a novel “NK+T” treatment that brings the best tumor-killing attributes of each engineered cell type to cancer patients, said CRISPR Therapeutics CEO Sam Kulkarni.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!